RPS6KA3 and hepatocellular carcinoma: Although mutations of Ras GTPases are found in only 2–4% of HCC patients, multiple activators and regulators of the pathway, such as FGF19, RSK2, RASAL1, RASSF1, and DUSPs, are more frequently mutated.